SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update

SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing tow

SPRO

Related stories